The ESPOIR cohort: A ten-year follow-up of early arthritis in France: Methodology and baseline characteristics of the 813 included patients

被引:143
作者
Combe, Bemard
Benessiano, Joealle
Berenbaum, Francis
Cantagrel, Alain
Daures, Jean-Pierre
Dougados, Maxime
Fardellone, Patrice
Fautrel, Bruno
Flipo, Rene-Marc
Goupille, Philippe
Guillemin, Francis
Le Loet, Xavier
Logeart, Isabelle
Marlette, Xavier
Meyer, Olvier
Ravaud, Philippe
Rincheval, Nathalle
Saraux, Alain
Schaeverbeke, Thierry
Sibilia, Jean
机构
[1] Univ Hosp, Montpellier, France
[2] Hop Xavier Bichat, Paris, France
[3] St Antoine Univ Hosp, Paris, France
[4] Univ Hosp, Toulouse, France
[5] Descartes Univ, Cochin Hosp, UPRES EA 4058, Paris, France
[6] Univ Hosp, Amiens, France
[7] Pitie Salpetriere Univ Hosp, Paris, France
[8] Univ Hosp, Lille, France
[9] Univ Hosp, Tours, France
[10] Univ Hosp, INSERM, C1E6, Nancy, France
[11] Univ Hosp, Rouen, France
[12] MSD, Paris, France
[13] Paris Sud Univ Hosp, Le Kremlin Bicetre, France
[14] Univ Hosp, Brest, France
[15] Univ Hosp, Bordeaux, France
[16] Univ Hosp, Strasbourg, France
关键词
ESPOIR cohort; rheumatoid arthritis; early arthritis; undifferentiated arthritis;
D O I
10.1016/j.jbspin.2007.06.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The French Society of Rheumatology initiated a large national multicenter, longitudinal and prospective cohort, the so-called "ESPOIR cohort study" in order to set up databases to allow various investigations on diagnosis, prognostic markers, epidemiology, pathogenesis and medico-economic factors in the field of early arthritis and rheumatoid arthritis. Methods: Patients were recruited if they had undifferentiated arthritis or rheumatoid arthritis, of less than 6 months disease duration and if they were DMARD and steroids naive. Patients have then to be followed every 6 months during the first 2 years then every year during at least 10 years. Clinical, biological. radiographic and medico-economic databases have been constituted to fit in the different objectives of the project and more than 20 scientific studies have already been accepted by the scientific committee. Results: 813 patients were included (76.75% were female). The mean age was 48.07 +/- 12.55 years. The mean delay from the onset of symptoms to referral to the rheumatologist was 74.8 +/- 76.6 days. Baseline swollen and tender joint counts were 7.19 +/- 5.37 and 8.43 +/- 7.01; DAS28 score was 5.11 +/- 1.31. CRP was abnormal in 38.9% of the patients; 44.2%, 45.8% and 38.8% had respectively IgM rheumatoid factor (RF), IgA RF and anti-CCP antibodies. HLA DRB 1 *01 or 04 genes were found in 56.7% of them. Finally, 22% of these patients had erosions on hand or feet at baseline. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:440 / 445
页数:6
相关论文
共 39 条
[1]   The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study [J].
Barrett, EM ;
Scott, DGI ;
Wiles, NJ ;
Symmons, DPM .
RHEUMATOLOGY, 2000, 39 (12) :1403-1409
[2]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[3]   Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443
[4]   EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) [J].
Combe, B. ;
Landewe, R. ;
Lukas, C. ;
Bolosiu, H. D. ;
Breedveld, F. ;
Dougados, M. ;
Emery, P. ;
Ferraccioli, G. ;
Hazes, J. M. W. ;
Klareskog, L. ;
Machold, K. ;
Martin-Mola, E. ;
Nielsen, H. ;
Silman, A. ;
Smolen, J. ;
Yazici, H. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) :34-45
[5]  
Combe B, 2003, J RHEUMATOL, V30, P2344
[6]  
Combe B, 2001, ARTHRITIS RHEUM, V44, P1736, DOI 10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO
[7]  
2-I
[8]  
Cunnane G, 2001, ARTHRITIS RHEUM-US, V44, P1744, DOI 10.1002/1529-0131(200108)44:8<1744::AID-ART309>3.0.CO
[9]  
2-K
[10]  
Dellhag B, 1999, ARTHRIT CARE RES, V12, P33, DOI 10.1002/1529-0131(199902)12:1<33::AID-ART6>3.0.CO